Investor Presentaiton
Novo Nordisk Annual Report 2023
Introducing Novo Nordisk
Strategic Aspirations
Risks
Management
Consolidated statements
Additional information
9.6 Facilitations of the Novo Nordisk Way
In 2023, a total of 42 units were facilitated and approximately 2,300 employees were
individually interviewed. In addition, feedback on those units was collected from
approximately 550 stakeholders. Out of the 42 units, one unit was assessed not to be
working in accordance with the Novo Nordisk Way, and for five units immediate actions
were required, which if not taken would lead to breaches of the Novo Nordisk Way.
Across all units facilitated, the accelerated growth and supply-demand challenges
are the two main factors which consistently impact the organisation and drive most
improvement opportunities from the facilitations conducted. The most frequent
observations raised to management teams for action are associated with five out of
our ten Essentials: 2) We set ambitious goals and are empowered to achieve them, 5)
We build and maintain good relations with our stakeholders, 7) We focus on
performance and personal development, 8) We have a healthy and engaging work
environment, and 9) We strive for agility and simplicity in everything we do.
ACCOUNTING POLICIES
Facilitations of the Novo Nordisk Way are measured as the number of facilitations
completed. A facilitation is an internal process for assessing adherence to the Novo
Nordisk Way. The assessments are based on a review of documentation and feedback
from stakeholders, followed by an on-site visit during which randomly selected
employees and management are interviewed. Identified gaps and improvement
opportunities related to the Novo Nordisk Way are presented to, and discussed with,
Management. The facilitators and Management agree on an action plan to address
those gaps and improvement opportunities. For the full list of the Novo Nordisk Way
Essentials, please refer to page 19 in the Management review.
9.7 Company reputation
Scale 0-100
People with diabetes
People with obesity
General practitioners
Diabetes specialists
Informed general public
Total score (average)
9.8 Animals purchased for research
2023
2022
2021
Number
2023
2022
2021
81.4
81.3
81.5
Mice, rats and other rodents
54,410
63,760
35,675
77.9
79.4
79.4 Pigs
608
427
759
82.9
84.0
84.8
Rabbits
289
606
184
88.9
90.3
90.3
Dogs
356
146
114
79.6
76.3
77.1
Non-human primates
807
700
495
82.1
82.3
82.6
Fish
36
14,098
10,638
Other vertebrates
2
13
14
56,508
79,750
47,879
Company reputation is a comprehensive approach to analysing reputational intelligence.
Novo Nordisk's excellent reputation score is driven by positive perceptions of products
and services, and by growing appreciation from the informed general public.
ACCOUNTING POLICIES
The reputation score is based on four factors measuring esteem, admiration, trust
and feeling of the stakeholders towards Novo Nordisk, across ten key markets: France,
Denmark, the US, Canada, Brazil, China, Japan, Germany, Italy and the UK. The data
is collected through online surveys carried out by an external consultancy firm.
Responses are aggregated to produce an overall score on a Likert scale of 1-7, which
is rebased on a 0-100 scale.
Total animals purchased
The number of animals purchased for research in 2023 decreased by 29% compared
to 2022. 96% of the animals purchased were rodents. The significant decrease in the
number of fish and rodents in 2023 is attributable, respectively, to specific research
projects using fish larvae that have been discontinued in the year, and to our
continuous efforts to reduce the number of animals used for research.
ACCOUNTING POLICIES
Animals purchased for research comprises the number of animals purchased for all
research undertaken by Novo Nordisk either in-house or by external contractors. The
number of animals purchased is based on internal registration of purchased animals
and yearly reports from external contractors.
94View entire presentation